Harrow had its Relative Strength (RS) Rating upgraded from 90 to 93 Friday.
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Decades of market research reveals that the best stocks often have an 80 or better RS Rating at the beginning of a new price run.
How To Use Stock Charts To Stay Profitable And Protected
Harrow is now considered extended and out of buy range after clearing a 20.31 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Harrow posted 0% EPS growth in the latest quarterly report. Sales gains came in at 44%. Keep an eye out for the company's next round of numbers on or around Mar. 13.
Harrow holds the No. 212 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
